Next Science (ASX:NXS) - Managing Director, Judith Mitchell
Managing Director, Judith Mitchell
Source: Women in STEMM Australia
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Next Science (NXS) has seen its XPERIENCE Surgical Solution cleared by Australia’s Therapeutic Goods Administration (TGA)
  • The TGA clearance allows for the sale of the no-rinse, antimicrobial solution in Australia
  • The company says it has received attention from organisations interested in partnering with Next Science, and is now in the process of evaluating commercialisation options for bringing XPERIENCE to the Australian market
  • Next Science shares were up 2.03 per cent, trading at $1.26 at 4:00 pm AEDT 

Next Science (NXS) has seen its XPERIENCE Surgical Solution cleared by Australia’s Therapeutic Goods Administration (TGA).

XPERIENCE is designed for use in open surgical procedures where the residual solution remains in the surgical site after closure. The no-rinse, antimicrobial solution is designed to defend against pathogens for several hours by rinsing away debris and micro-organisms, giving surgeons a simple adjunct to help prevent surgical site and post-operative infections.

The TGA clearance allows for the sale of XPERIENCE in Australia.

XPERIENCE is currently sold in the US market where the product received a 510(k) clearance from the US Food and Drug Administration (FDA) in April this year.

The initial sales focus for XPERIENCE in the US has been the orthopaedic, plastic and reconstructive surgery markets.

“Surgical site infections are a major cause of surgical complications and increased morbidity and mortality across the world,” explained Managing Director Judith Mitchell.

“XPERIENCE provides an enormous opportunity to help reduce surgical site infections, save lives and reduce healthcare costs that arise from perioperative infections.”

The company said it has received strong inbound attention from organisations interested in partnering with Next Science, and is now in the process of evaluating commercialisation options for bringing XPERIENCE to the Australian market.

Next Science shares were up 2.03 per cent, trading at $1.26 at 4:00 pm AEDT.

NXS by the numbers
More From The Market Online
The words "Market Open ASX 200 Futures Tip FLAT" appear stacked atop one another next to ASX today company iconography.

ASX Market Open: December malaise before Chrissy holidays leaves bourse trundling near-flat | Dec 17

ASX today – The fairly dour end to December trading looks to have settled in for…
Market concept

(Last) Market Close (of 2025): October back again as DRO, EOS & 4DX pop; otherwise mid day

If you wanted to feel like you were re-living the festivity season for the XJO that was October, look no further than today’s

EV Resources on ‘accelerated pathway’ to Los Lirios restart after strong antimony recovery tests

EV Resources is inching closer to a Los Lirios restart after strong metallurgical results set up…
Magneto scan concept

MRI scans changed medicine – what disruptive tech is next? Enter Compumedics, up +50% YoY

Compumedics, a biotech company developing its Orion Lifespan MEG product, could just be the next big…